Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.17
NAS:DEPO's Cash to Debt is ranked lower than
89% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. NAS:DEPO: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
NAS:DEPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 11.77 Max: No Debt
Current: 0.17
Equity to Asset 0.24
NAS:DEPO's Equity to Asset is ranked lower than
91% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:DEPO: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
NAS:DEPO' s Equity to Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.36 Max: 0.97
Current: 0.24
-2.63
0.97
F-Score: 3
Z-Score: 1.19
M-Score: -2.91
WACC vs ROIC
19.13%
-1.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.11
NAS:DEPO's Operating margin (%) is ranked lower than
77% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. NAS:DEPO: -4.11 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:DEPO' s Operating margin (%) Range Over the Past 10 Years
Min: -601.86  Med: -14.47 Max: 72.49
Current: -4.11
-601.86
72.49
Net-margin (%) -16.89
NAS:DEPO's Net-margin (%) is ranked lower than
81% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. NAS:DEPO: -16.89 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:DEPO' s Net-margin (%) Range Over the Past 10 Years
Min: -555.44  Med: -13.99 Max: 75.05
Current: -16.89
-555.44
75.05
ROE (%) -23.10
NAS:DEPO's ROE (%) is ranked lower than
80% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. NAS:DEPO: -23.10 )
Ranked among companies with meaningful ROE (%) only.
NAS:DEPO' s ROE (%) Range Over the Past 10 Years
Min: -333.8  Med: 20.07 Max: 532.43
Current: -23.1
-333.8
532.43
ROA (%) -5.57
NAS:DEPO's ROA (%) is ranked lower than
75% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. NAS:DEPO: -5.57 )
Ranked among companies with meaningful ROA (%) only.
NAS:DEPO' s ROA (%) Range Over the Past 10 Years
Min: -66.64  Med: -6.53 Max: 73.87
Current: -5.57
-66.64
73.87
ROC (Joel Greenblatt) (%) -148.98
NAS:DEPO's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. NAS:DEPO: -148.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:DEPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2282.52  Med: -260.35 Max: 8060.52
Current: -148.98
-2282.52
8060.52
Revenue Growth (3Y)(%) 35.40
NAS:DEPO's Revenue Growth (3Y)(%) is ranked higher than
92% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. NAS:DEPO: 35.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:DEPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.4  Med: 25.5 Max: 517.8
Current: 35.4
-74.4
517.8
EBITDA Growth (3Y)(%) 43.20
NAS:DEPO's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. NAS:DEPO: 43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:DEPO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: 6.7 Max: 84.1
Current: 43.2
-55.5
84.1
EPS Growth (3Y)(%) 17.60
NAS:DEPO's EPS Growth (3Y)(%) is ranked higher than
66% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NAS:DEPO: 17.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:DEPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.5  Med: -6.3 Max: 180.8
Current: 17.6
-59.5
180.8
» NAS:DEPO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DEPO Guru Trades in Q3 2015

Jim Simons 104,146 sh (New)
Paul Tudor Jones 40,800 sh (+56.32%)
Joel Greenblatt 264,236 sh (-68.63%)
» More
Q4 2015

DEPO Guru Trades in Q4 2015

John Hussman 200,000 sh (New)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 30,900 sh (-24.26%)
» More
Q1 2016

DEPO Guru Trades in Q1 2016

Steven Cohen 1,866,629 sh (New)
John Hussman 200,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

DEPO Guru Trades in Q2 2016

Joel Greenblatt 47,318 sh (New)
Steven Cohen Sold Out
John Hussman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:PCRX, OTCPK:PNHNF, NAS:SUPN, NYSE:LCI, NAS:INNL, NYSE:DPLO, NAS:IPXL, NAS:EGRX, NAS:SGYP, OTCPK:KHTRF, NAS:AMPH, NAS:MNTA, OTCPK:SHPHF, NAS:IRWD, NAS:SGNT, NAS:HRTX, OTCPK:EVOTF, OTCPK:LPCUF, NAS:SCMP, NAS:ACET » details
Traded in other countries:DPO.Germany,
DepoMed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.

Ratios

vs
industry
vs
history
Forward P/E 14.95
DEPO's Forward P/E is ranked higher than
64% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.76 vs. DEPO: 14.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 27.45
DEPO's Price/Owner Earnings (ttm) is ranked higher than
61% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.08 vs. DEPO: 27.45 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DEPO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.68  Med: 7.61 Max: 212
Current: 27.45
2.68
212
P/B 5.04
DEPO's P/B is ranked lower than
71% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. DEPO: 5.04 )
Ranked among companies with meaningful P/B only.
DEPO' s P/B Range Over the Past 10 Years
Min: 2  Med: 4.2 Max: 22.64
Current: 5.04
2
22.64
P/S 3.40
DEPO's P/S is ranked lower than
56% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. DEPO: 3.40 )
Ranked among companies with meaningful P/S only.
DEPO' s P/S Range Over the Past 10 Years
Min: 1.38  Med: 3.42 Max: 210.94
Current: 3.4
1.38
210.94
PFCF 12.83
DEPO's PFCF is ranked higher than
82% of the 193 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. DEPO: 12.83 )
Ranked among companies with meaningful PFCF only.
DEPO' s PFCF Range Over the Past 10 Years
Min: 2.31  Med: 9.31 Max: 265.87
Current: 12.83
2.31
265.87
POCF 12.50
DEPO's POCF is ranked higher than
67% of the 256 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. DEPO: 12.50 )
Ranked among companies with meaningful POCF only.
DEPO' s POCF Range Over the Past 10 Years
Min: 2.28  Med: 9.25 Max: 251.36
Current: 12.5
2.28
251.36
EV-to-EBITDA 23.90
DEPO's EV-to-EBITDA is ranked lower than
64% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. DEPO: 23.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: 1 Max: 124.5
Current: 23.9
-582.9
124.5
Shiller P/E 154.22
DEPO's Shiller P/E is ranked lower than
91% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.59 vs. DEPO: 154.22 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s Shiller P/E Range Over the Past 10 Years
Min: 72.14  Med: 117.71 Max: 1535
Current: 154.22
72.14
1535
Current Ratio 1.06
DEPO's Current Ratio is ranked lower than
86% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. DEPO: 1.06 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3 Max: 56
Current: 1.06
0.57
56
Quick Ratio 1.01
DEPO's Quick Ratio is ranked lower than
76% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. DEPO: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.94 Max: 56
Current: 1.01
0.57
56
Days Inventory 45.20
DEPO's Days Inventory is ranked higher than
86% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. DEPO: 45.20 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 45.2  Med: 226.72 Max: 613.73
Current: 45.2
45.2
613.73
Days Sales Outstanding 66.31
DEPO's Days Sales Outstanding is ranked higher than
60% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. DEPO: 66.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 347.08
Current: 66.31
12.13
347.08
Days Payable 47.76
DEPO's Days Payable is ranked lower than
69% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. DEPO: 47.76 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 142.64 Max: 1113.92
Current: 47.76
30.8
1113.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.20
DEPO's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. DEPO: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DEPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.9  Med: -9.45 Max: -2.2
Current: -2.2
-58.9
-2.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.77
DEPO's Price/Projected FCF is ranked lower than
53% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. DEPO: 2.77 )
Ranked among companies with meaningful Price/Projected FCF only.
DEPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.18  Med: 2.23 Max: 335
Current: 2.77
1.18
335
Price/Median PS Value 1.00
DEPO's Price/Median PS Value is ranked higher than
66% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. DEPO: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 3.61 Max: 394
Current: 1
0.44
394
Earnings Yield (Greenblatt) (%) -1.10
DEPO's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DEPO: -1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DEPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.1  Med: 17.25 Max: 266.4
Current: -1.1
-1.1
266.4

More Statistics

Revenue (TTM) (Mil) $437.5
EPS (TTM) $ -1.22
Beta1.46
Short Percentage of Float24.48%
52-Week Range $12.25 - 25.50
Shares Outstanding (Mil)61.37

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 482 585 675
EPS ($) 1.21 1.64 2.13
EPS w/o NRI ($) 1.21 1.64 2.13
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed Inc (DEPO): Starboard Value LP Schedules Special Meeting of Shareholders Sep 22 2016
Report: Depomed Is Attempting to Sell Itself Sep 20 2016
[$$] Depomed to Hold Nov. 15 Shareholder Meeting Sep 19 2016
Arbor and Purdue Seen as Likely Bidders for DepoMed Sep 19 2016
Here’s Why These Five Stocks Are Trending on Monday Sep 19 2016
Starboard sets date for special meeting of Depomed shareholders Sep 19 2016
Starboard delivers special shareholder meeting request to Depomed Sep 19 2016
Starboard Delivers Special Meeting Request to Depomed and Issues Letter to Depomed Shareholders Sep 19 2016
Depomed Receives Request to Call Special Meeting of Shareholders Sep 16 2016
Depomed Receives Request to Call Special Meeting of Shareholders Sep 16 2016
US STOCKS-Futures drop with oil prices Sep 16 2016
40 Trading Lessons from The PlayBook Sep 16 2016
Calls look for more gains in Depomed Sep 16 2016
Depomed (DEPO) Stock Soars Amid Sale Speculation Sep 16 2016
Depomed Inc (DEPO), Oracle Corporation (ORCL) & More: Why These Stocks Are Making Headlines Sep 16 2016
The Market In 5 Minutes: A Down Week Comes To A Close Sep 16 2016
DepoMed shares jump on report drugmaker preparing sale Sep 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)